Hypervirulent Klebsiella pneumoniae

Junjun Chen1,2, Huan Zhang1,3, Xuelian Liao1,2

  • 1Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

PubMed

Insights

Hypervirulent Klebsiella pneumoniae (hvKP) infections, particularly multidrug-resistant strains (MDR-hvKP), cause severe, metastatic abscesses. Understanding hvKP virulence factors and their evolution is crucial for developing new treatments.

Area of Science:

  • Microbiology and Infectious Diseases
  • Molecular Biology and Genetics
  • Immunology

Background:

  • Hypervirulent Klebsiella pneumoniae (hvKP) causes severe, rapidly metastatic infections with high mortality.
  • Multidrug-resistant hvKP (MDR-hvKP) poses a growing global health threat.
  • Key virulence factors include iron acquisition systems, capsule production, colibactin, and hypermucoviscosity.

Purpose of the Study:

  • To review and summarize recent advances in understanding hvKP hypervirulence factors.
  • To explore potential therapeutic targets for hvKP and MDR-hvKP infections.
  • To investigate the co-evolution of hypervirulence and multidrug resistance.

Main Methods:

  • Literature review of recent advances in hvKP research.
  • Analysis of virulence factors, including novel co-existence with multidrug resistance elements.
  • Screening for superplasmids carrying both hypervirulence and multidrug resistance genes.

Main Results:

  • Identified key virulence factors contributing to hvKP lethality.
  • Highlighted the novel co-existence of hypervirulence and multidrug resistance, often on mobile superplasmids.
  • Noted the acceleration in the evolution of virulence and multidrug resistance.

Conclusions:

  • Further research is needed to fully elucidate hvKP virulence mechanisms.
  • Innovative therapeutic targets are critical for combating MDR-hvKP.
  • Development of reliable diagnostic methods for hvKP and MDR-hvKP is essential.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
336
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
268
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
223
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
359